drugset
drugset / Trial / NCT02836158

Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL

NCT02836158 ↗

Phase 2/3 Recruiting 100 enrolled Navy General Hospital, Beijing
NaSingle-groupOpen-labelTreatment

Summary

This study suggests that R-IDARAM combined with intrathecal immunochemotherapy may be high effective in elderly patients with primary central nervous system lymphoma (PCNSL).

Timeline

Start
2010-09
Primary completion
2025-12
Completion
2030-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 50 mg Intrathecal
Subject Cytarabine Small molecule 1 g Intrathecal
Subject Dexamethasone Small molecule 5 mg Intrathecal
Subject Dexamethasone Small molecule 100 mg/m2 Intrathecal
Subject Idarubicin Small molecule 10 mg/m2 —
Subject Methotrexate Small molecule 15 mg Intrathecal
Subject Methotrexate Small molecule 1.5 g Intrathecal
Subject Rituximab Monoclonal antibody 20 mg Intrathecal
Subject Rituximab Monoclonal antibody 375 mg/m2 Intrathecal

Indications

primary central nervous system lymphoma